Actively Recruiting
Prognostic Significance of ctDNA in HL
Led by Interni hematologicka klinika FNKV · Updated on 2024-02-16
500
Participants Needed
5
Research Sites
312 weeks
Total Duration
On this page
Sponsors
I
Interni hematologicka klinika FNKV
Lead Sponsor
C
Charles University, Czech Republic
Collaborating Sponsor
AI-Summary
What this Trial Is About
Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.
CONDITIONS
Official Title
Prognostic Significance of ctDNA in HL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years or older with newly confirmed classical Hodgkin lymphoma
- Signed informed consent form
You will not qualify if you...
- Patients who have not signed the informed consent form
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
University Hospital Hradec Kralove
Hradec Králové, Czechia, 50005
Actively Recruiting
2
University Hospital Olomouc
Olomouc, Czechia, 77520
Actively Recruiting
3
University Hospital Kralovske Vinohrady
Prague, Czechia, 10034
Actively Recruiting
4
Charles University
Prague, Czechia, 12108
Active, Not Recruiting
5
General University Hospital
Prague, Czechia, 12808
Actively Recruiting
Research Team
H
Heidi Mocikova, M.D., Ph.D.
CONTACT
O
Ondrej Havranek, assoc. prof.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here